KBI Biopharma, Inc., a JSR Life Sciences company, appointed Tony Fraij, chief operating officer; Shaguna Seth, chief of staff and global PMO leader; Katie Edgar, senior vice president of corporate strategy and alliance management; and Sarah Wakefield, senior vice president, corporate communications.

Fraij brings extensive experience as an operations leader of multiple global pharmaceutical and biotech companies. He will utilize his expertise in personnel development, engineering, and technical operations to strategically guide KBI’s daily operations, ensuring optimal efficiencies and supporting company growth. Fraij will lead operations teams globally, including manufacturing, IT, and engineering. Fraij previously served as senior vice president and general manager at AGC Biologics, vice president of technical operations at Novartis, and director of operations at Boehringer Ingelheim.

Seth is a seasoned business and technology executive who excels at driving operational execution and performance. Seth will leverage more than two decades of experience in translational research, pharmaceutical development, manufacturing, and program management, and apply expertise in biologics and RNA-based drug development. Seth previously served as AGC Biologics’ interim general manager and vice president of process development.

Edgar will work closely with the KBI and JSR Life Science teams to identify strategic growth initiatives and opportunities, elevate partnership management and performance, and help fulfill the company’s industry-leading vision. With a background in strategy and operations, business development, mergers and acquisitions, and portfolio and alliance management, Edgar will provide crucial support in aligning objectives across the KBI and JSR networks and propel KBI’s transformation plan forward.

Wakefield brings 20 years of experience to KBI, with many of those years spent in the healthcare and biotech industries. Wakefield expertise lies in building high-performing marketing and communications teams and processes to increase brand awareness, drive revenue growth, enhance communications, and foster an inclusive culture. Wakefield will contribute valuable leadership skills in executive strategy, marketing, branding and identity, DEI initiatives, project management, and organizational and team development.

“I am thrilled to welcome these four exceptional experts to KBI,” said J.D. Mowery, KBI Biopharma CEO. “Each of them brings unique insight, has an impressive track record, and is fully aligned with our KBI vision as we navigate the evolving landscape of our industry and seize opportunities for success. They will all play vital roles in shaping our future at KBI, enabling us to be the best and most trusted partner to our global biopharmaceutical customers.”